Trial Profile

Phase I/II trial of BL 8040 in combination with sorafenib in AML patients with FLT3-ITD mutation

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Motixafortide (Primary) ; Sorafenib (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors BioLineRx

Most Recent Events

19 May 2016 According to a BioLineRx Ltd. media release, the company will present results of this Phase 2a study at the European Hematology Association 21st Congress. Also, the detailed results from this Phase 2a study will be presented at an upcoming US-based scientific conference.
10 Mar 2016 Planned initiation date changed from 1 Mar 2015 to 1 Jul 2016, as per BioLineRx media release.
17 Dec 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com